KRYS Krystal Biotech Inc

Krystal Biotech to Present at H.C. Wainwright 24th Annual Global Investment Conference

Krystal Biotech to Present at H.C. Wainwright 24th Annual Global Investment Conference

PITTSBURGH, Sept. 08, 2022 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the H.C. Wainwright 24th Annual Global Investment Conference in New York from September 12-14.

Krish Krishnan, Chairman and Chief Executive Officer, will deliver a presentation and host investor meetings on September 13.

A webcast of the presentation will be available beginning at 2:30pm ET on Tuesday, September 13 and will be posted on the Investor section of the Company’s .

About Krystal Biotech, Inc.

Krystal Biotech, Inc. (NASDAQ: KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform and in-house manufacturing capabilities to develop life-changing medicines for patients with serious diseases, including rare diseases in skin, lung, and other areas. For more information please visit , and follow @KrystalBiotech on and .

CONTACT:

Investors and Media:                                                                

Meg Dodge                                                      

Krystal Biotech                                                    

                                            

Source: Krystal Biotech, Inc.



EN
08/09/2022

Underlying

KRYSKrystal Biotech Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Krystal Biotech Inc

Free Trial
KRYS Krystal Biotech...

Krystal Biotech Inc: 1 director

A director at Krystal Biotech Inc sold/sold after exercising options 60,161 shares at 267.270USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direct...

KRYS KRYSTAL BIOTECH INC
02/27/26 February 27, 2026 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech to Present at TD Cowen 46th Annual Health Care Confere...

Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference PITTSBURGH, Feb. 24, 2026 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026, in Boston. Company executives will take part in a fireside chat scheduled at 3:10 pm ET and host investor meetings throughout the day. A webcast of the presentation will be available beginning at 3:10 pm ET on Tuesday, March 3, 2026 and will be posted on the Investors section of the Company’s . About Krystal Biotech, In...

February 24, 2026 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial ...

Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results $107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB111 for the treatment of HHD Strong balance sheet, ending the quarter with $955.9 million in cash and investments PITTSBURGH, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today reported financial results for the fourth quarter and full year ending December 31, 2025 and provided a business ...

February 17, 2026 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial ...

Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 PITTSBURGH, Feb. 10, 2026 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS) announced today that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026, prior to the open of U.S. markets. The Company’s management will also host a conference call and webcast at 8:30 am ET on Tuesday, February 17, 2026, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: . For those u...

February 10, 2026 1 EN
 PRESS RELEASE
Free
KRYS Krystal Biotech...

Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for...

Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer PITTSBURGH, Feb. 09, 2026 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to KB707, the Company’s redosable immunotherapy designed to drive sustained, localized expression of interleukin-2 and interleukin-12 in the tumor microenvironment, for the treatment of advanced or metastatic non-small cell lung cancer (NS...

February 9, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch